Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma, Inc. reports developments in clinical-stage immunology therapeutics and immune-modulating biologics. Company updates center on its Immuno-STAT platform, the autoimmune and inflammatory disease candidate CUE-401, a clinical-stage dual-mechanism anti-IgE antibody for allergic diseases, and collaboration activity involving B cell depletion programs such as CUE-501.
Recurring news also covers leadership changes, inducement equity awards, shareholder-approved capital actions, research presentations, milestone payments, licensing activity, and other corporate matters tied to Cue Biopharma's Nasdaq-listed common stock and clinical-stage operating model.
Cue Biopharma (Nasdaq:CUE) reported second quarter 2026 collaboration revenue of $7.9 million, up from $3.0 million a year earlier, primarily from a Boehringer Ingelheim preclinical milestone. Operating expenses rose sharply, with R&D at $49.0 million and G&A at $46.6 million, driven largely by one-time cash and non-cash items related to the CUE-221 license from Ascendant and a strategic transformation.
Other expense included a substantial non-cash loss tied to liability-classified warrants, leading to a net loss of $153.1 million versus $8.5 million in 2025. Cash and equivalents were $17.4 million at June 30, 2026, with a subsequent $50 million private placement completed. Cue submitted an IND for CUE-221 in food allergy, expects Phase 2 data in chronic spontaneous urticaria by end of Q3 2026, and plans to initiate a CUE-401 Phase 1 study by year-end. The company also added a new CMO/Head of R&D and CFO.
Cue Biopharma (Nasdaq:CUE) appointed veteran biotech finance executive James M. Ahlers as Chief Financial Officer, reporting to President and CEO Shao-Lee Lin, M.D., Ph.D. The company highlighted his 25+ years of experience across public and private biotechnology companies, including nearly two decades as CFO of Intarcia Therapeutics and senior roles at Titan Pharmaceuticals and Ansan Pharmaceuticals.
Cue also recently submitted an Investigational New Drug (IND) application to the FDA for CUE-221 in food allergy and expects a Phase 2 CSU data readout for this program by the end of the quarter. In connection with his appointment, Ahlers received inducement equity awards under Nasdaq Listing Rule 5635(c)(4): a non-qualified stock option to purchase 51,000 shares and 25,500 restricted stock units, both vesting over four years, with the option exercise price set at $30.40, the July 30, 2026 closing price.
Cue Biopharma (Nasdaq: CUE) appointed Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development, reporting to President and CEO Shao-Lee Lin, M.D., Ph.D. The physician-scientist and immunology expert joins as Cue advances its clinical programs in allergic and autoimmune diseases.
Cue expects a Phase 2 CSU data readout for its CUE-221 program by the end of the third quarter of 2026 and plans to initiate a Phase 1 trial of CUE-401, a bifunctional IL-2 and TGF-β molecule, by the end of the fourth quarter. According to Cue, a recently announced $50 million private placement is intended to further fund clinical development. In connection with his appointment, Dr. Borie received inducement awards comprising a stock option for 63,000 shares and 31,500 restricted stock units, both vesting over four years.
Cue Biopharma (Nasdaq:CUE) entered a securities purchase agreement for a $50.0 million private placement with accredited investors, comprising 1,418,071 common shares at $33.21 per share and pre-funded warrants for up to 87,500 shares at $33.209 each. The pre-funded warrants are immediately exercisable at $0.001 per share and remain exercisable until fully exercised. Closing is expected on or about July 13, 2026, subject to customary conditions. The placement is led by Cormorant Asset Management with additional new funds including Columbia Threadneedle Investments. Cue Biopharma plans to use net proceeds to support clinical development and general corporate purposes and highlights upcoming data from Ascendant Health’s ongoing Phase 2 CSU study in China, expected by the end of the third quarter of 2026. The securities are unregistered under the Securities Act, and the company has agreed to file a registration statement for resale.
Cue Biopharma (Nasdaq:CUE) announced a major board transition supporting its evolution toward late-stage clinical operations. Effective May 29, 2026, four independent directors resigned, while Daniel Camardo, a former CEO and commercial leader, and Viola Meehan, an experienced CFO and board member, joined the board to strengthen commercial and strategic finance capabilities.
Cue Biopharma (Nasdaq:CUE), a clinical-stage therapeutics company developing therapies for immunological disorders, announced that president and CEO Shao-Lee Lin will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 3:10 p.m. EDT in New York City.
A live audio webcast, replay, and 90-day archive will be available on Cue Biopharma’s investor relations website.
Cue Biopharma (Nasdaq:CUE) reported Q1 2026 collaboration revenue of $5.7 million, up from $0.4 million in Q1 2025, and a net loss of $5.2 million, reduced from $12.3 million. R&D expenses fell to $6.9 million, G&A held at $4.2 million.
The company licensed CUE-221, a Phase 2 anti-IgE asset for allergic disease, and advanced CUE-401, an autoimmune candidate. Liquidity was strengthened by a $30 million private placement and a $7.5 million milestone from Boehringer Ingelheim. Shao-Lee Lin, M.D., Ph.D., was appointed President and CEO.
Cue Biopharma (Nasdaq: CUE) announced inducement equity awards on May 3, 2026, to seven new employees including newly appointed president and CEO Shao-Lee Lin, M.D., Ph.D. Grants include a non-statutory option for 655,074 shares and 327,537 RSUs for Dr. Lin, plus aggregate option grants of 518,599 shares and 327,534 RSUs to six other new employees. Options use an exercise price of $30.42 per share (May 1, 2026 close). Dr. Lin’s option vests monthly over four years; her RSUs were fully vested on grant. Other employees’ options vest quarterly over four years; their RSUs vested on grant.
Cue Biopharma (NASDAQ: CUE) announced a private placement expected to raise approximately $30 million in gross proceeds via pre-funded warrants and accompanying warrants. The PIPE is expected to close on or about May 4, 2026, subject to customary conditions and stockholder approval.
Proceeds are intended to advance the clinical pipeline, including acquiring and developing Ascendant-221, and for working capital and general corporate purposes. Newbridge Securities is placement agent; resale registration will be filed with the SEC.
Cue Biopharma (Nasdaq: CUE) entered an exclusive license agreement for Ascendant-221, a Phase 2 anti-IgE antibody, gaining global rights excluding mainland China, Hong Kong, Macau and Taiwan.
Deal consideration includes a $15 million upfront fee, up to $676.5 million in milestone payments and tiered royalties. Ascendant-221 Phase 2 results from a China study are expected in 2H 2026; Cue plans a global Phase 2b in food allergy after data review.